Results 271 to 280 of about 29,420 (294)
Some of the next articles are maybe not open access.
Expert Review of Anti-infective Therapy, 2005
The echinocandins are a novel class of antifungal agents that have come into use over the past 10 years. The mechanism of action of these lipopeptide agents is via noncompetitive inhibition of the synthesis of 1,3-beta-glucans, which are fungal cell wall constituents. All agents of this class are only available in an intravenous formulation.
openaire +3 more sources
The echinocandins are a novel class of antifungal agents that have come into use over the past 10 years. The mechanism of action of these lipopeptide agents is via noncompetitive inhibition of the synthesis of 1,3-beta-glucans, which are fungal cell wall constituents. All agents of this class are only available in an intravenous formulation.
openaire +3 more sources
Caspofungin: An echinocandin antifungal agent
Clinical Therapeutics, 2002The mainstays of treatment for nosocomial fungal infections have been amphotericin B and azole derivatives. Caspofungin acetate is a new echinocandin antifungal agent with a mechanism of action that targets a structural component of the fungal cell wall.This article describes the pharmacologic properties and potential clinical usefulness of caspofungin.
Horatio B. Fung +2 more
openaire +3 more sources
Pediatric Drugs, 2009
Caspofungin is the first echinocandin to be approved for the treatment of fungal infections in pediatric patients. The antifungal properties of caspofungin result from interference with fungal cell-wall integrity. In vitro, caspofungin is fungicidal against Candida spp.
Karly P. Garnock-Jones, Susan J Keam
openaire +3 more sources
Caspofungin is the first echinocandin to be approved for the treatment of fungal infections in pediatric patients. The antifungal properties of caspofungin result from interference with fungal cell-wall integrity. In vitro, caspofungin is fungicidal against Candida spp.
Karly P. Garnock-Jones, Susan J Keam
openaire +3 more sources
Caspofungin in the treatment of invasive fungal infections
Intensive and Critical Care Nursing, 2006Caspofungin is a member of a new class of antifungals called Echinocandins and is the first to have marketing authorisation in the United Kingdom. This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of caspofungin.
Simon Keady, Meera Thacker
openaire +3 more sources
Journal of Infection, 2005
The objective was to prospectively assess the efficacy and safety of caspofungin as salvage therapy for invasive aspergillosis in patients enrolled in the caspofungin compassionate-use study.Forty-eight patients with invasive Aspergillus infections (36 with pulmonary infection, 12 with extrapulmonary or disseminated infection) were enrolled in this ...
Arlene Taylor +4 more
openaire +3 more sources
The objective was to prospectively assess the efficacy and safety of caspofungin as salvage therapy for invasive aspergillosis in patients enrolled in the caspofungin compassionate-use study.Forty-eight patients with invasive Aspergillus infections (36 with pulmonary infection, 12 with extrapulmonary or disseminated infection) were enrolled in this ...
Arlene Taylor +4 more
openaire +3 more sources
Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND In recent decades, Candida glabrata has emerged as a frequent cause of life-threatening fungal infection. In C. glabrata, echinocandin resistance is associated with mutations in FKS1/FKS2 (β-1,3-glucan synthase).
A. Ceballos Garzón +4 more
semanticscholar +1 more source
BACKGROUND In recent decades, Candida glabrata has emerged as a frequent cause of life-threatening fungal infection. In C. glabrata, echinocandin resistance is associated with mutations in FKS1/FKS2 (β-1,3-glucan synthase).
A. Ceballos Garzón +4 more
semanticscholar +1 more source
Experiences with the use of caspofungin in paediatric patients
Mycoses, 2008SummaryInvasive fungal infections are important causes for treatment‐related morbidity and mortality in severely immunocompromised paediatric patients with haematological malignancies or in children undergoing haematopoietic stem cell transplantation. In addition, neonates, in particular preterm infants, are at risk for invasive mycoses.
Andreas H. Groll, Thomas Lehrnbecher
openaire +3 more sources
Caspofungin therapy in immunocompromised children and neonates
Expert Review of Anti-infective Therapy, 2011The prevalence of invasive fungal infections is increasing and the infections are becoming a major problem in immunocompromised children and neonates. Fortunately, there has been a recent surge in the development of new antifungal agents. Caspofungin, the first licensed echinocandin, is a novel class of antifungal and is approved for use in children 3 ...
Nuran Salman +2 more
openaire +3 more sources
Caspofungin: when and how? The microbiologist’s view
Mycoses, 2011SummaryThe echinocandins are antifungal agents, which act by inhibiting the synthesis of β‐(1,3)‐d‐glucan, an integral component of fungal cell walls. Caspofungin, the first approved echinocandin, demonstrates good in vitro and in vivo activity against a range of Candida species and is an alternative therapy for Aspergillus infections.
Cornelia Lass-Flörl +2 more
openaire +3 more sources
Case Report: Beyond the Blood-retina Barrier: Intravitreal Caspofungin for Fungal Endophthalmitis.
Optometry and Vision Science, 2020SIGNIFICANCE Two fungal endophthalmitis cases demonstrate safety and efficiency of intravitreal caspofungin as a new therapy option in fungal endophthalmitis. PURPOSE The purpose of this study was to evaluate the intravitreal application of caspofungin
B. von Jagow +2 more
semanticscholar +1 more source